We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment, and teamwork, and so can you. We are currently recruiting for an IFS Lead (Principal IFS Support Analyst) to join the Information Systems (IS) team. The purpose of this role is to develop, maintain and support the use of IFS and future GxP systems. The role holder handles advising business teams and where applicable, supporting the transition to future systems. This whilst keeping compliance and quality standards throughout. Our Information Systems Team interfaces with all areas of the business to provide day to day support, ensuring operational effectiveness for all employees. Responsible for all business systems, the team looks for innovative solutions to protect and meet the business’s digitisation needs. Your responsibilities in this role would be: • The day-to-day IFS operation, support and troubleshooting across the business. • Collaboration with multiple departments to ensure IFS functionality and benefits are being realised by the business. • Working with business process owners to understand business requirements, recommend, design, specify and implement solutions in IFS and other GxP systems. • Identification, development and support of PL SQL, Custom Events & Actions, Crystal Reporting and BAU development work. • Maintaining documentation of IFS changes and developments. • Manage and oversee vendors including IFS and DBA provider. • Lead development partners on larger scale activities. • Working with IT Operations colleagues to manage technical operating environments. • Collaboration with Validation and QA leads in the preparation and execution of system changes. • Supporting transition to future GxP systems. We are looking for: • A degree level education within Software development, Life Sciences, or the equivalent level of work experience. • Experience with IFS version 9, ideally gained in a regulated industry. GxP experience is essential. • In-depth knowledge of permission sets, user-based profiles, troubleshooting system issues and diagnosing and solving hardware or software faults. • Experience in managing complex needs of stakeholder groups, explaining what is possible and translation to system requirements. • Communication and collaboration are essential to success. • Readiness to play a key role within the IS Team and cross departmentally to ensure that IFS and other GxP systems are being effectively improved. • Ability to prioritise and plan the implementation of a backlog of work. • Solid foundation in relevant programming languages and frameworks. (experience with Python and SQL is preferable) • Knowledge and understanding of an Oracle Database and services. • Experience in installing and configuring updates, Oracle database backup, refresh, restore and service monitoring. About Us: Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing ability in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: • Highly competitive reward packages • Wellbeing programmes • Development opportunities • Welcoming, friendly, supportive colleagues • A diverse and inclusive working environment • Our values are: Deliver Innovation, Be Inspiring and Have Integrity • State of the art laboratory and manufacturing facilities We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment, and teamwork, and so can you. Collaborate. Contribute. Change lives. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.